CN Patent
CN119504796B — 一种具有抗肿瘤活性的化合物及其应用
Assigned to Affiliated Hospital of Nantong University · Expires 2026-03-10 · 0y expired
What this patent protects
本发明公开了一种具有抗肿瘤活性的化合物及其应用。所述化合物的结构式如式Ⅰ所示: 本发明提供的化合物具有抗肿瘤活性,体外抗肿瘤活性试验结果表明,这个新化合物对肝癌细胞、胃癌细胞、胰腺癌细胞、肺癌细胞、乳腺癌细胞均具有抑制作用。
USPTO Abstract
本发明公开了一种具有抗肿瘤活性的化合物及其应用。所述化合物的结构式如式Ⅰ所示: 本发明提供的化合物具有抗肿瘤活性,体外抗肿瘤活性试验结果表明,这个新化合物对肝癌细胞、胃癌细胞、胰腺癌细胞、肺癌细胞、乳腺癌细胞均具有抑制作用。
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.